Japanese Co Drags APL to US Court

Published: 28th January 2015 06:01 AM  |   Last Updated: 28th January 2015 06:01 AM   |  A+A-

HYDERABAD: Japanese firm Shionogi Inc has dragged Aurobindo Pharma Ltd (APL) to the US District Court of Illionois allegedly for infringing its patent.

As per a petition filed by Shionogi, Aurobindo sought approval from the USFDA to sell a generic version of Shionogi’s doripenem for injection - marketed under brand name Doribax - in the US market prior to the expiration of the original patent.

Doribax is a prescription drug used as an antibacterial agent. According to Shionogi, in August, 2012, the US Patent and Trademark Office had legally issued patents entitled ‘Crystal Form of Pyrrolidylthiocarbapenem Derivative’, and continues to hold all substantial rights.

It also said Shionogi holds the New Drug Application approved by the FDA for the marketing and sale of doripenem for injection, 250 mg/vial and 500 mg/vial.

As per Aurobindo ANDA filing, it sought FDA approval to engage in the commercial manufacture, use, offer for sale, and sale of a generic version of doripenem for injection. “Aurobindo’s submission of the Aurobindo ANDA including a paragraph IV certification constitutes infringement of one or more claims of the ’402 patent, either literally or under the doctrine of equivalents”, it said.

Stay up to date on all the latest Business news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp